A patient with anxiety and depression who experienced side effects on bupropion (Wellbutrin) 150 mg daily and escitalopram (Lexapro) 10 mg daily, what alternative antidepressant options are recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Switch to Sertraline or Consider Mirtazapine

Given that both bupropion and escitalopram caused intolerable side effects, switch to sertraline as the next pharmacologic option, or consider mirtazapine if sedation and appetite stimulation would be beneficial. For patients with prominent anxiety and depression who have failed two antidepressants, switching to another second-generation antidepressant (SGA) shows similar efficacy across agents 1.

Rationale for Switching Strategy

The American College of Physicians guidelines indicate that switching from one SGA to another demonstrates no significant difference in response or remission rates 1. Moderate-quality evidence shows comparable outcomes when switching between bupropion, sertraline, or venlafaxine 1. This means your patient has reasonable odds of tolerating and responding to a different agent despite two prior failures.

Why Sertraline Next?

  • Broad tolerability profile: Sertraline is generally well-tolerated and has extensive evidence in both depression and anxiety disorders
  • Different side effect profile than escitalopram: While both are SSRIs, individual responses vary significantly
  • Proven efficacy in anxious depression: The patient's "bad" anxiety makes an SSRI/SNRI reasonable despite the lexapro failure
  • Sertraline was specifically studied in the switching trials referenced in guidelines 1

Why Consider Mirtazapine?

Mirtazapine offers a mechanistically distinct approach (alpha-2 antagonist enhancing norepinephrine and serotonin) 2:

  • Rapid onset: Significant improvement within 1-2 weeks, faster than typical SSRIs 2
  • Anxiolytic properties: Blocks 5-HT2 and 5-HT3 receptors, providing anxiety relief 2
  • Favorable for specific presentations: If the patient has insomnia, poor appetite, or weight loss, mirtazapine's sedating and appetite-stimulating effects become therapeutic rather than adverse 2
  • Lower sexual dysfunction risk: Unlike SSRIs, sexual side effects are uncommon 2

Key caveat: Sedation and weight gain are common with mirtazapine, so avoid if the patient is already sedated or overweight 2.

Alternative Considerations

Venlafaxine (SNRI)

  • Another option from switching trials with similar efficacy 1
  • Dual norepinephrine/serotonin action may help both depression and anxiety
  • Monitor blood pressure as a potential side effect

Vilazodone or Vortioxetine

  • Vilazodone: SSRI + 5-HT1A partial agonist with reduced sexual side effects and faster onset 2
  • Vortioxetine: Multimodal serotonin modulator with cognitive benefits 2
  • Both show efficacy in 2-4 weeks with better tolerability profiles than older SSRIs 2
  • Consider if cost/insurance coverage permits

What About Augmentation Instead?

Switching is preferred over augmentation at this stage. The guidelines show that augmenting with bupropion or buspirone has similar efficacy to switching 1, but since the patient already failed bupropion monotherapy, augmentation with it seems less logical. Cognitive behavioral therapy (CBT) as augmentation or switch shows equivalent outcomes to medication switches 1, making it a valuable concurrent option.

Critical Pitfalls to Avoid

  1. Don't restart bupropion at higher doses: The patient already experienced side effects at 150 mg daily. While bupropion can help anxiety in some patients 3, 4, recent evidence suggests SSRIs may have a modest advantage in highly anxious presentations 3

  2. Taper escitalopram appropriately: Abrupt SSRI discontinuation risks withdrawal symptoms. Cross-taper when switching to another serotonergic agent

  3. Start low, go slow: Begin sertraline at 25-50 mg daily, mirtazapine at 15 mg nightly. Titrate based on response and tolerability

  4. Screen for bipolar disorder: Before any antidepressant switch, ensure no history of mania/hypomania, as antidepressants can precipitate manic episodes 5

  5. Monitor for worsening: Early treatment phases carry increased risk for suicidal ideation, agitation, and anxiety worsening 5. Close follow-up in first 2-4 weeks is essential

Practical Implementation

Week 0-1:

  • Taper escitalopram (if recently taken) while starting sertraline 25-50 mg daily OR mirtazapine 15 mg nightly
  • Educate about expected timeline (2-4 weeks for response)

Week 2-4:

  • Assess tolerability and early response
  • Titrate sertraline to 100-150 mg or mirtazapine to 30 mg if tolerated and needed

Week 6-8:

  • Evaluate full response
  • If inadequate response but tolerated, consider augmentation with CBT or dose optimization before switching again

The evidence consistently shows that various SGAs have similar efficacy when used as switch strategies 6, 1, so the key is finding one the patient can tolerate long enough to achieve therapeutic effect.

References

2
Research

Other Antidepressants.

Handbook of experimental pharmacology, 2019

4
Research

Bupropion and Anxiety: A Brief Review.

Human psychopharmacology, 2025

Related Questions

What is the recommended medication taper and adjustment for an 87‑year‑old woman with major depressive disorder, generalized anxiety disorder, and dementia who is taking bupropion 150 mg daily, escitalopram 5 mg at bedtime, and a Deluxe Teen supplement?
What is the appropriate initiation, titration, and monitoring plan for bupropion maintenance therapy in a 27-year-old woman with mixed anxiety and depressive disorder?
In a 59-year-old female nursing-home resident with depression, anxiety, and a history of alcohol abuse who is taking bupropion XL (bupropion) 300 mg daily, escitalopram 20 mg daily, trazodone 100 mg at bedtime and 25 mg in the morning, amphetamine/dextroamphetamine (Adderall) 10 mg daily, and divalproex sodium (Depakote) 250 mg twice daily, and who now presents with worsening depression, social isolation, increased daytime sleepiness, and anhedonia, what is the optimal psychotropic treatment approach?
Is bupropion extended‑release (XL) 150 mg appropriate for anxiety, and should the dose be increased to 300 mg?
In a 23-year-old male with anxiety and depression who smokes and wishes to quit, is bupropion (Wellbutrin) an appropriate treatment choice?
Should paroxetine (Paxil) be discontinued before initiating Auvelity (dextromethorphan/bupropion)?
Can allopurinol tablets be split or crushed for administration?
In a patient with preserved renal function and acute pyelonephritis, is metamizole (dipyrone) a safer second-line antipyretic than NSAIDs?
Which of the following statements about epilepsy is NOT true?
What are the safest pharmacologic options for insomnia in a patient who has recently undergone coronary artery bypass graft (CABG) surgery?
What recent literature supports the updated diagnostic and therapeutic approach for an elderly post‑coronary artery bypass grafting (CABG) patient presenting with unexplained dizziness, vomiting, and episodic severe hypertension?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.